… Here we describe newly emerging non-dopaminergic therapeutic strategies for PD, … of
multiple disease states, understanding of the etiology of PD in non-dopaminergic regions as well …

… of these problems, specific pharmacological therapies that target the relevant non-dopaminergic …
Our goal for this section is to review novel non-dopaminergic treatments that are under …

… non-dopaminergic treatments are now in clinical use to treat motor … use for non-dopaminergic
drugs is as add-on therapy for motor … Several non-dopaminergic agents have also been …

… of dopamine replacement therapy. This review updates advancements in non-dopaminergic
treatments for motor control in PD since 2013. To date, no non-dopaminergic selective drug …

… useful in the treatment of parkinsonian symptoms. For this reason, nondopaminergic drugs
are … potent new antiparkinsonian drug, has been tested in clinical studies. Budipine is a potent …

… , autonomic dysfunction, and neuro-endocrinal problems. A recent review has described
the role of non-dopaminergic treatments in clinical trials aimed at management of some non-…

… In this review, we discuss potential non-dopaminergic approaches to treatment of PD …
Agents targeting non-dopaminergic pathways are also being actively explored for treatment …

… does not cover the large number of non-dopaminergic treatment options. For more background
… treatment, we recommend the Movement Disorder Society Evidence-Based Medicine …

… I and II studies on novel non-dopaminergic treatment approaches based on this model of …
This review presents three examples of this type of non-dopaminergic drug therapy. …

… of non-dopaminergic neurotransmitter systems in the brain. This evidence has prompted an
interest in developing drugs that target non-dopaminergic … of non-dopaminergic targets that …